Cargando…

Advances in protein subunit vaccines against tuberculosis

Tuberculosis (TB), also known as the “White Plague”, is caused by Mycobacterium tuberculosis (Mtb). Before the COVID-19 epidemic, TB had the highest mortality rate of any single infectious disease. Vaccination is considered one of the most effective strategies for controlling TB. Despite the limitat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Xu, Jin-chuan, Hu, Zhi-dong, Fan, Xiao-yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465801/ https://www.ncbi.nlm.nih.gov/pubmed/37654500 http://dx.doi.org/10.3389/fimmu.2023.1238586

Ejemplares similares

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development
por: Hu, Zhidong, et al.
Publicado: (2022)

Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
por: Afkhami, Sam, et al.
Publicado: (2020)

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis
por: Bellini, Chiara, et al.
Publicado: (2020)

Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa
por: Wan, Chuang, et al.
Publicado: (2019)

Subunit vaccines for Acinetobacter baumannii
por: Yang, Ning, et al.
Publicado: (2023)

Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine
por: Hao, Ling, et al.
Publicado: (2020)

Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to M. Tuberculosis Infection
por: Riccomi, Antonella, et al.
Publicado: (2019)

Immunogenicity and protective efficacy of OmpA subunit vaccine against Aeromonas hydrophila infection in Megalobrama amblycephala: An effective alternative to the inactivated vaccine
por: Zhang, Minying, et al.
Publicado: (2023)

A platform technology for generating subunit vaccines against diverse viral pathogens
por: Young, Andrew, et al.
Publicado: (2022)

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani
por: Duthie, Malcolm S., et al.
Publicado: (2018)

A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation
por: Jiang, Fan, et al.
Publicado: (2023)

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria
por: Nagpal, Gandharva, et al.
Publicado: (2018)

A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2(+) T Cells
por: Yu, Qi, et al.
Publicado: (2017)

Identification and Evaluation of Recombinant Outer Membrane Proteins as Vaccine Candidates Against Klebsiella pneumoniae
por: Zhang, Bao-Zhong, et al.
Publicado: (2021)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
por: Basheer, Amina, et al.
Publicado: (2023)

A Novel Whole Yeast-Based Subunit Oral Vaccine Against Eimeria tenella in Chickens
por: Soutter, Francesca, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
por: Liao, Yuting, et al.
Publicado: (2022)

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
por: Tran, Thi Nhu Mai, et al.
Publicado: (2021)

Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium tuberculosis Infection
por: Chen, Yingying, et al.
Publicado: (2019)

Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates
por: Zhou, Fangbin, et al.
Publicado: (2023)

Vaccine development against tuberculosis before and after Covid-19
por: Kaufmann, Stefan H. E.
Publicado: (2023)

Editorial: Reassessing Twenty Years of Vaccine Development against Tuberculosis
por: Schaible, Ulrich E., et al.
Publicado: (2018)

Gut Dysbiosis Thwarts the Efficacy of Vaccine Against Mycobacterium tuberculosis
por: Nadeem, Sajid, et al.
Publicado: (2020)

Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches
por: Dong, Rong, et al.
Publicado: (2020)

The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01(E) and MVA85A
por: Ullah, Inayat, et al.
Publicado: (2020)

Editorial: Research advances of tuberculosis vaccine and its implication on COVID-19
por: Gong, Wenping, et al.
Publicado: (2023)

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
por: Kaufmann, Stefan H. E., et al.
Publicado: (2017)

Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity
por: Schaible, Ulrich E., et al.
Publicado: (2017)

Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology
por: Kaufmann, Stefan H. E.
Publicado: (2020)

Progressive Host-Directed Strategies to Potentiate BCG Vaccination Against Tuberculosis
por: Negi, Kriti, et al.
Publicado: (2022)

Adjuvants and Antigen-Delivery Systems for Subunit Vaccines against Tuberculosis
por: Mustafa, Abu Salim
Publicado: (2021)

Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice
por: Xin, Qi, et al.
Publicado: (2013)

Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection
por: Liang, Yan, et al.
Publicado: (2023)

The Profile of T Cell Responses in Bacille Calmette–Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine
por: Hu, Zhidong, et al.
Publicado: (2018)

Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human
por: Zhang, Yuwei, et al.
Publicado: (2022)

Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction
por: Li, Hu, et al.
Publicado: (2023)

Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design
por: Liu, Xin, et al.
Publicado: (2023)

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis
por: Billeskov, Rolf, et al.
Publicado: (2018)

Novel Chimeric Protein Vaccines Against Clostridium difficile Infection
por: Wang, Shaohui, et al.
Publicado: (2018)

Immunological effects of the PE/PPE family proteins of Mycobacterium tuberculosis and related vaccines
por: Guo, Fangzheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s118bc5haoumqf89j7b1orqv46